Pfizer
Robert E. Hellauer III has a strong background in data science and research. Robert E. is currently working at Pfizer as the Director/Team Lead for Data Science. Prior to Pfizer, they served as the Lead Director for Data Science - Clinical Trial Services at CVS Health, where they led a team of data scientists and worked on various cross-functional initiatives. Before CVS Health, Robert worked at Known as the Director of Data Science, leading consulting engagements and implementing AI and ML methods for various clients in different industries. Robert E. started their career at the University of Maryland as a Graduate Research Assistant, where they studied subatomic particles and trained machine learning models. Robert also worked at The Johns Hopkins University Applied Physics Laboratory in different roles.
Robert E. Hellauer III earned their Doctor of Philosophy (Ph.D.) degree in Physics from the University of Maryland from 2008 to 2015. Prior to that, they obtained their Bachelor of Science (B.S.) degree with High Honors in Physics from the University of Maryland from 2004 to 2008. Robert E. completed their high school education at McDonogh School from 2000 to 2004.
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.